Press Releases

• Cellectis: Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL More
• Daiichi Sankyo: Showcases Strength of Industry-Leading ADC Portfolio With Latest Research Updates From Five Landmark Breast Cancer Trials at SABCS More
• Feinstein Institutes: Research Pinpoints Core Cause of Vascular Cognitive Impairment, Unlocking New Therapeutic Avenues for Cognitive Decline More
• Johnson & Johnson: INLEXZO (Gemcitabine Intravesical System) Delivers 74 Percent Disease-Free Survival at One Year in BCG-Unresponsive, High-Risk, Papillary-Only NMIBC More
• Kallyope: Positive Results From Phase 2b Study of Elismetrep for the Acute Treatment of Migraine More More*
• Legend Biotech: New CARVYKTI Data in Multiple Myeloma and First-in-Human Results From Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025 More
• Newron: US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS) More
• Pfizer: HYMPAVZI (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents With Hemophilia A or B With Inhibitors More More
• Regeneron: Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment More More More*
• Secura Bio: Extended Follow Up Analyses From Phase 2 PRIMO Trial in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma at the 2025 American Society of Hematology Meeting More
• SELLAS Life Sciences: Positive Phase 2 Data of SLS009 in Combination With AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 More
• Soligenix: Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad More
• Syndax: Leadership in Menin Inhibition at ASH 2025 With Multiple Revuforj (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum More

Financial News

• Get Full Access to BYTE51 Life Sciences Intelligence for 50% Off More
• HUTCHMED: Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China More
  
• JPM Week Conference Readiness Packages (Big4Bio Subscriber Discount) More
• Oppenheimer & Co.: Strengthens Equities and Biotech Research Teams With Addition of Kostas Biliouris, Ph.D. More

Media/Misc Coverage

• ASH: BMS’s Iberdomide Shows Efficacy in Myeloma Maintenance More*
• Biotech Hangout: Episode 165 Podcast
• More on Bristol Myers Expanding Breyanzi Approval to Marginal Zone Lymphoma More* More* More
  
• Onyx @ Jefferies: David Hung, CEO, Nuvation Bio Video
  
• Subscribe to LifeSci Startup for Updates on US Startups More
• The Big4Bio Podcast: Every Moment Matters: Transforming Discovery With Organoids Podcast

Companies

Career Center

• Ex-Intercept CEO Takes Over at Altimmune; Carolyn Bertozzi Leaves Alnylam’s Board More*
  
• ICYMI: CEO's Perspective: Big Moves Come with Big Responsibilities More
  
• ICYMI: CEO's Perspective: The High Cost of Job Hopping More
• ICYMI: Elevating Executive Presence: A Blueprint for Life Sciences and Biotech Leaders More
• ICYMI: The Power of Peer Learning: Why Even Top Biotech Leaders Need Mentorship More
• ICYMI: What’s Next in Precision Medicine: Leadership Challenges and Opportunities More
• Job Postings in November Tick Up–But So Do Applications More

• Compounding Pharmacy Compliance (Save 10% with VIP code: 25B4B10) Dec 9-10
• PBM Contracting Summit (Save 10% with VIP code: 25B4B10) Dec 9-10
  
• Trade and Channel Strategies (Save 10% with VIP code: 25B4B10) Dec 9-11
• The Power of Presenting at Biotech Showcase Dec 10
  
• Advancing Drug Development Forum Dec 11
• Know Before You Go: AI in 2026 — Signals, Risks, and Real-World Impact (Pre-JPM Event) Jan 6
• BLPN Investor Summit Jan 8-10
  

NYC Sponsors